188 related articles for article (PubMed ID: 16304187)
1. Caspofungin and liposomal amphotericin B therapy of experimental murine scedosporiosis.
Bocanegra R; Najvar LK; Hernandez S; McCarthy DI; Graybill JR
Antimicrob Agents Chemother; 2005 Dec; 49(12):5139-41. PubMed ID: 16304187
[TBL] [Abstract][Full Text] [Related]
2. Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis.
Ortoneda M; Capilla J; Pastor FJ; Serena C; Guarro J
Diagn Microbiol Infect Dis; 2004 Dec; 50(4):247-51. PubMed ID: 15582297
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
[TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK.
Bruynesteyn K; Gant V; McKenzie C; Pagliuca T; Poynton C; Kumar RN; Jansen JP
Eur J Haematol; 2007 Jun; 78(6):532-9. PubMed ID: 17419744
[TBL] [Abstract][Full Text] [Related]
5. Caspofungin versus liposomal amphotericin B for empirical therapy.
Schneemann M; Imhof A
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675094
[No Abstract] [Full Text] [Related]
6. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis.
Sionov E; Mendlovic S; Segal E
J Infect; 2006 Aug; 53(2):131-9. PubMed ID: 16360214
[TBL] [Abstract][Full Text] [Related]
7. Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans.
Rodríguez MM; Calvo E; Serena C; Mariné M; Pastor FJ; Guarro J
Antimicrob Agents Chemother; 2009 May; 53(5):2153-5. PubMed ID: 19223617
[TBL] [Abstract][Full Text] [Related]
8. A novel murine model of cerebral scedosporiosis: lack of efficacy of amphotericin B.
Capilla J; Mayayo E; Serena C; Pastor FJ; Guarro J
J Antimicrob Chemother; 2004 Dec; 54(6):1092-5. PubMed ID: 15509616
[TBL] [Abstract][Full Text] [Related]
9. An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy.
Ellis M; Frampton C; Joseph J; Alizadeh H; Kristensen J; Hauggaard A; Shammas F
J Med Microbiol; 2006 Oct; 55(Pt 10):1357-1365. PubMed ID: 17005784
[TBL] [Abstract][Full Text] [Related]
10. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.
Clemons KV; Espiritu M; Parmar R; Stevens DA
Antimicrob Agents Chemother; 2005 Dec; 49(12):4867-75. PubMed ID: 16304147
[TBL] [Abstract][Full Text] [Related]
12. Trichosporon asahii infection treated with caspofungin combined with liposomal amphotericin B.
Bassetti M; Bisio F; Di Biagio A; Pierri I; Balocco M; Soro O; Cruciani M; Bassetti D
J Antimicrob Chemother; 2004 Aug; 54(2):575-7. PubMed ID: 15231763
[No Abstract] [Full Text] [Related]
13. An update on the use of antifungal agents.
Martinez R
J Bras Pneumol; 2006; 32(5):449-60. PubMed ID: 17268750
[TBL] [Abstract][Full Text] [Related]
14. Caspofungin versus liposomal amphotericin B for empirical therapy.
Kontoyiannis DP; Lewis RE
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15673808
[No Abstract] [Full Text] [Related]
15. Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections.
Nivoix Y; Zamfir A; Lutun P; Kara F; Remy V; Lioure B; Rigolot JC; Entz-Werlé N; Letscher-Bru V; Waller J; Levêque D; Koffel JC; Beretz L; Herbrecht R
J Infect; 2006 Jan; 52(1):67-74. PubMed ID: 16368463
[TBL] [Abstract][Full Text] [Related]
16. Caspofungin versus liposomal amphotericin B for empirical therapy.
Tattevin P; Bareau B; Camus C
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675091
[No Abstract] [Full Text] [Related]
17. Successful combined antifungal salvage therapy with liposomal amphothericin B and caspofungin for invasive Aspergillus flavus infection in a child following allogeneic bone marrow transplantation.
Kriván G; Sinkó J; Nagy IZ; Goda V; Reményi P; Bátai A; Lueff S; Kapás B; Réti M; Tremmel A; Masszi T
Acta Biomed; 2006; 77 Suppl 2():17-21. PubMed ID: 16918062
[TBL] [Abstract][Full Text] [Related]
18. Nebulized liposomal amphotericin B and combined systemic antifungal therapy for the treatment of severe pulmonary aspergillosis after allogeneic hematopoietic stem cell transplant for a fatal mitochondrial disorder.
Castagnola E; Moresco L; Cappelli B; Cuzzubbo D; Moroni C; Lanino E; Faraci M
J Chemother; 2007 Jun; 19(3):339-42. PubMed ID: 17594932
[TBL] [Abstract][Full Text] [Related]
19. Caspofungin in combination with amphotericin B against Candida glabrata.
Barchiesi F; Spreghini E; Fothergill AW; Arzeni D; Greganti G; Giannini D; Rinaldi MG; Scalise G
Antimicrob Agents Chemother; 2005 Jun; 49(6):2546-9. PubMed ID: 15917570
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model.
Imai J; Singh G; Fernandez B; Clemons KV; Stevens DA
J Antimicrob Chemother; 2005 Jul; 56(1):166-71. PubMed ID: 15917284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
